Accelerating Access for Patients Act of 2022 This bill modifies requirements relating to accelerated approval of drugs for serious or life-threatening diseases or conditions, including by requiring guidance from the Food and Drug Administration and coordinated plans with product sponsors on appropriate postapproval studies.